[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Citations 0
This Week in JAMA
March 8, 2000

This Week in JAMA

JAMA. 2000;283(10):1251. doi:10.1001/jama.283.10.1251

JAMA-EXPRESS: β-Blocker Therapy Improves Outcomes of ChronicCHF

In previously published results of the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF), which enrolled 3991 patients with congestive heart failure (CHF) and systolic dysfunction, total mortality was 34% lower among patients assigned to receive controlled-release/extended-release metoprolol (metoprolol CR/XL) in addition to standard therapy than in the placebo group. In this report on outcomes of the MERIT-HF trial during a mean follow-up of 12 months, Hjalmarson and colleaguesArticle found that patients in the metoprolol CR/XL group had a lower risk of total mortality or all-cause hospitalization and of mortality or hospitalization due to worsening heart failure, improved symptoms of heart failure, and better quality of life compared with patients in the placebo group. In an editorial, Califf and O'ConnorArticle discuss why most patients with heart failure due to systolic dysfunction do not receive β-blocker therapy despite evidence of its effectiveness and present ways to increase its use in eligible patients.

Rethinking Treatment of Opioid Dependence

Methadone maintenance therapy for opioid dependence has been shown to be effective but requires indefinite treatment with a dependence-producing medication and, in the United States, specialty care in methadone maintenance clinics. In this trial comparing traditional methadone maintenance treatment with a 180-day program of opioid detoxification supplemented with intense psychosocial services, Sees and colleaguesArticle found that treatment retention was higher in the methadone maintenance treatment group than in the detoxification program, and rates of heroin use and drug-related HIV risk behaviors were lower. Weinrich and StuartArticle describe 2 large opioid treatment programs in Scotland that integrate primary care, specialty care, and methadone maintenance. The proportion of injection drug users enrolled in these programs (60% to 80% in Edinburgh; 41% to 73% in Glasgow) greatly exceeds that in the United States (14% of heroin addicts). In an editorial, Rounsaville and KostenArticle discuss issues of access and quality of care for treatment of opioid dependence.

Extraimmunization Among Young Children

Using data from the US 1997 National Immunization Survey, Feikema and colleaguesArticle found that 21% of 22,806 children received an extra immunization with at least 1 vaccine. In an editorial, DavisArticle observes that these findings do not warrant a change in current immunization practices, but suggests that more effort be directed toward creating a complete and accurate immunization history for each child.

Early and Later Response to Osteoporosis Treatment

To determine whether women who lose bone mineral density (BMD) during the first year of treatment for osteoporosis will continue to lose BMD if the same treatment is continued, Cummings and colleagues analyzed data from women enrolled in 2 clinical trials who completed 2 years of BMD monitoring and adhered to study medication—5 mg/d of alendronate sodium in the Fracture Intervention Trial; 60 or 120 mg/d of raloxifene hydrochloride in the Multiple Outcomes of Raloxifene Evaluation trial. In both trials, most women who lost BMD during the first year of treatment gained BMD in the second year. Women who lost the most BMD in the first year gained the most in year 2, consistent with regression to the mean.

See Article

Magnet Therapy Not Helpful for Low Back Pain

Therapy with permanent magnets is used for the treatment of musculoskeletal conditions, but few studies have evaluated its effectiveness. In this crossover trial that enrolled 20 patients with chronic low back pain, Collacott and colleagues found no differences between treatment with bipolar permanent magnets and sham magnet devices on measures of pain intensity, pain quality, or lumbosacral range of motion.

See Article

Contempo Updates

Helicobacter pylori cytotoxin-associated gene A (cagA) gene and risk of clinical gastrointestinal disease in persons infected with H pylori.

See Article

Medical News & Perspectives

With the advent of at least partial peace in the Balkans, psychiatrists from the war-torn region are attempting to help survivors cope with their residual mental trauma.

See Article

Injuries Among Jockeys

Incidence and pattern of injuries among professional jockeys during official horse races at US tracks.

See Article

Judicious Use of Antiretroviral Therapy

How selection and timing of antiretroviral therapy for human immunodeficiency virus infection determine risk of drug resistance and may constrain treatment options and alter response to future therapy.

See Article

JAMA Patient Page

For your patients: Information about opioid dependence and treatment.

See Article